Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax has expanded its agreement with Defiante Farmaceutica, an affiliate of the pharmaceutical group Sigma-Tau (Sigma-Tau) for Kalbitor (ecallantide), indicated for the treatment of hereditary angioedema (HAE) and other therapeutic indications.
Subscribe to our email newsletter
With this expansion, the companies expect to develop and commercialize the HAE drug in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea.
Under their existing agreement, Defiante holds these rights in Europe, North Africa, the Middle East, Russia, Australia and New Zealand.
However, Dyax has retained rights to Kalbitor in other territories, including the US.
Defiante will responsible to a pay a sum of $7m to Dyax including $10m in regulatory, approval and reimbursement milestones.
Consistent with their existing agreement, Dyax is also eligible to receive sales milestones and royalties equal to 41% of net sales of Kalbitor, less cost of goods sold.
Sigma-Tau is also responsible for costs associated with regulatory approval and commercialization in their additional territories.
Sigma-Tau Group Executive vice president and CEO Ugo Di Francesco said the addition of these territories to their agreement enhances their global offerings in the specialty pharmaceutical business and gives them the opportunity to provide an important new treatment option to HAE patients in Latin America and Southeast Asia.